Ludwig Institute for Cancer Research Limited

Alnylam Pharmaceuticals, Inc.

University of California

Abbott Laboratories Corporation

Alnylam Europe Ag

Webster K Cavenee

Frank Furnari

Pamela Tan

Dinah Sah

Maria Del Mar Inda Perez

Rudy Bonavia

Lloyd J Old

Gerd J Ritter

Elisabeth Stockert

Achim Jungbluth

Terrance Grant Johns

H-j Su Huang

Con Panousis

Antony Wilks Burgess

Andrew Ewart Scott

Edouard Collins Nice

Christoph Renner

Anne Murray

George Mark

Andrew Mark Scott

Huei-Jen Su Huang

Motoo Nagane

Peter Collins

Erwin G Van Meir

Erwin Van Meir

Su Huang

Anthony Wilks Burgess

Terrance Grant Jonhs

Andrew Scott

Huei-Jen Huang

Gerd Ritter

Elizabeth Stockert

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.

Compositions and methods for inhibiting expression of mutant EGFR gene

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.

Treatment method using EGFR antibodies and SRC inhibitors and related formulations

The invention relates to compositions which include both a DR5 binding ligand, such as TRAIL, and a DNA damaging agent. In combination, these two materials have unexpected efficacy in treating conditions involving rapid cellular turnover, such as cancer, where an increase in apoptosis is desired. The compositions are particularly effective in treating neoplasias and diseases involving proliferative lesions, such as glioma.

Compositions of trail and DNA damaging drugs and uses thereof

Glioblastoma-derived angiogenesis inhibiting factor

A glioblastoma derived angiogenesis inhibiting factor is described. The material is induced in presence of wild type p53, but not by several mutated forms of p53. Various uses of the material are described.

Glioblastoma cell lines that produce angiogenesis inhibiting factor

Growing community of inventors

Del Mar, CA, United States of America

Webster K Cavenee